Project Grant R01HL170156
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$757K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45267, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $445,000.00 to The Children's Hospital Of Philadelphia Research Institute to conduct research on the role of neutrophil extracellular traps (NETs) in thromboinflammatory diseases. The key objectives are to: 1) characterize the role of NETs in immune homeostasis, 2) define the mechanism by which platelet factor 4 (PF4) and an Fc-modified antibody enhance NET-mediated...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $602,955 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to National Jewish Health in Denver, Colorado. The 5-year grant, running from July 2024 to June 2029, will fund research to identify the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active lung repair. The primary objectives are to: 1) Test the hypothesis that a subset of airspace...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports the construction of a multi-scale 3D AI-powered map of genetic factors and cellular interactions driving normal and aberrant lung development in childhood interstitial lung disease (CHILD). The project will leverage single-cell and spatial...
This $203,974 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to investigate the effects of normal and diseased extracellular matrix (ECM) on the self-renewal and differentiation of airway basal epithelial cells. The project leverages novel tools developed by the co-PIs, including "inside-out" airway organoids and ECM hydrogels derived from normal and...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $798,727 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania (University of Pennsylvania) for the "The Penn LungMAP 3 Team: Defining Chronic Lung Disease" project. This 5-year effort aims to expand understanding of human lung diseases, with a focus on cataloging cellular and molecular changes in chronic lung diseases like COPD and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, in the amount of $1,788,091.00 with a start date of August 1, 2024 and end date of April 30, 2028. The purpose of this grant is to investigate the mechanisms underlying impaired resolution of inflammation in the lungs of patients with cystic fibrosis (CF) and to...
This Project Grant award of $915,924 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate how disruptions to early-life microbial colonization of the lungs, such as through antibiotic use, can lead to chronic respiratory diseases by remodeling the developmental pathways of lung-resident immune cells and epithelial cells. The research aims to define the specific microbial taxa essential for establishing lung homeostasis...
The University of Tennessee Health Science Center received a $615,455 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award, effective September 1, 2024 through June 30, 2028, supports research to investigate the role of eosinophils in promoting antibacterial immunity against Streptococcus pneumoniae, a leading cause of bacterial pneumonia that often co-occurs with influenza infections. The...
This Project Grant award of $579,309, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research conducted by the University of Toledo's Health Science Campus Division. The project aims to investigate the role of cysteinyl leukotriene receptor signaling in regulating the inflammatory and proliferative functions of macrophages, and its impact on lung inflammation in response to acute lung injury. The research will...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $759,983.00 to the University of North Carolina at Chapel Hill to investigate neutrophil function and the lung microenvironment during Streptococcus pneumoniae pneumonia and acute lung injury. The study aims to determine how neutrophils change as they are recruited and function during pneumonia, compare neutrophils defined by specific criteria, and examine changes...